A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy Adults
Open Access
- 1 March 2009
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 199 (5) , 711-716
- https://doi.org/10.1086/596558
Abstract
Development of live attenuated influenza vaccines (LAIV) against avian strains with pandemic potential is an important public-health strategy. EitherKeywords
This publication has 20 references indexed in Scilit:
- Evaluation of Replication and Pathogenicity of Avian Influenza A H7 Subtype Viruses in a Mouse ModelJournal of Virology, 2007
- A dose–response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adultsVaccine, 2007
- Three Indonesian Clusters of H5N1 Virus Infection in 2005New England Journal of Medicine, 2006
- Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine PreparationsClinical Infectious Diseases, 2006
- Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and FerretsPLoS Medicine, 2006
- Development of Effective Vaccines against Pandemic InfluenzaImmunity, 2006
- Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidateVaccine, 2003
- Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccinesMedical Microbiology and Immunology, 2002
- Principles Underlying the Development and Use of Live Attenuated Cold-Adapted Influenza A and B Virus VaccinesViral Immunology, 2002
- Cytotoxic T-Cell Immunity to InfluenzaNew England Journal of Medicine, 1983